Canadian Life Sciences Database

The New Era of Project Optimus: Implications for Oncology Development Strategy, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn about the Project Optimus initiative for dose optimization in early-phase oncology drug development. Attendees will learn how it has impacted early-phase oncology study designs. The featured speakers will share lessons learned and best practices in interpreting the guidance based on tangible examples and real-world case studies.

TORONTO, Sept. 10, 2024 /PRNewswire-PRWeb/ -- Initially drafted in January 2023 and finalized in August 2024, the US Food and Drug Administration (FDA) released guidance tied to Project Optimus, titled "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases."

The expert speakers will provide tangible examples and case studies of how drug development has played out in the Project Optimus era.

Project Optimus recommends oncology drug developers move away from traditional approaches of determining the maximum tolerated dose to building dose optimization strategies into clinical development plans that balance safety, tolerability and efficacy.

Since the release of the guidance, early-phase oncology drug development has shifted dramatically, including new dose escalation designs (a 3+3 is no more), larger sample sizes, real-time PK/PD sampling, randomization between doses and global reach for patient access.

While the new guidance has led to larger sample sizes, larger global footprints and higher study costs, Project Optimus aims to ensure a more robust safety and efficacy profile early in the development cycle. This can result in streamlined later-phase studies and a more comprehensive understanding of the asset, enhancing the probability of registrational success.

In this webinar, the expert speakers will provide tangible examples and case studies of how drug development has played out in the Project Optimus era. By reviewing case studies and their experiences, they will uncover lessons learned and best practices in interpreting the guidance, in addition to exploring the changing regulatory landscape.

Join experts Gilles Gallant, BPharm, PhD, FOPQ, Chief Development Officer, Mythic Therapeutics; Joe Shan, Vice President, Clinical Operations, Adcentrx Therapeutics, and from Catalyst Oncology: Andrew Zupnick, PhD, Vice President, Oncology Drug Development; and Meredith Manuel, Executive Director, Consulting; for the live webinar on Wednesday, September 25, 2024, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit The New Era of Project Optimus: Implications for Oncology Development Strategy.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com

For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com/

View original content to download multimedia:https://www.prweb.com/releases/the-new-era-of-project-optimus-implications-for-oncology-development-strategy-upcoming-webinar-hosted-by-xtalks-302242936.html